Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics, Inc. (KROS) director Jean Jacques Bienaime reported an open-market purchase of common stock. On 2026-08-17, he purchased 1,000 shares at a weighted average price of $10.27 per share, executed in multiple trades between $10.02 and $10.39. Following this transaction, he directly holds 19,592 shares of Keros Therapeutics common stock. The purchase was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
Keros Therapeutics, Inc. (KROS) director Charles W. Newton has filed a notice under Rule 144 for a planned sale of common stock through UBS Financial Services Inc. The filing lists a proposed sale of 551 shares of Keros common stock, related to restricted stock units (RSUs) from the issuer with an indicated date of August 15, 2026. The filing also notes a prior sale in the last three months of 550 shares of Keros common stock on June 11, 2026.
Annita Tanini, Corporate Controller and VP, Finance of Keros Therapeutics, Inc., reports her initial beneficial ownership of the company’s equity. She directly holds 46,368 shares of Common Stock, including 11,940 restricted stock units (RSUs) that vest in multiple tranches through 2027, subject to continued service.
She also holds several employee stock options on Common Stock, including options for 25,000 shares at $28.74 per share, 6,000 shares at $70.93, 7,500 shares at $46.30, 10,000 shares at $54.38, 14,800 shares at $56.18, and 7,800 shares at $15.52, with expirations ranging from 2030 to 2036. Certain options are immediately exercisable, while others vest over time in quarterly installments.
Keros Therapeutics provided an updated corporate presentation describing its strategy as a clinical-stage biopharmaceutical company focused on disorders linked to dysfunctional TGF-β superfamily signaling. Lead candidate rinvatercept (KER-065), a modified activin receptor type II ligand trap, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
The presentation reports generally favorable safety and pharmacodynamic data from a Phase 1 healthy volunteer trial and outlines an ongoing open-label Phase 2 basket trial in DMD (about 24 patients) with initial data expected in the first half of 2027. Preclinical data in DMD and ALS models suggest effects on muscle mass, bone, fat, inflammation and neuromuscular junction integrity. A second asset, elritercept (KER-050), is licensed globally (excluding certain Greater China territories) to Takeda, with a $200 million upfront payment, potential milestones of over $1.1 billion, and tiered royalties, alongside the ongoing Phase 3 RENEW trial in myelodysplastic syndromes.
Keros Therapeutics, a clinical-stage biopharmaceutical company focused on TGF-ß–related disorders, reported Q2 2026 with no revenue versus $18.2 million a year earlier, and first-half 2026 revenue of $0.4 million versus $229.4 million, reflecting the absence of prior-year Takeda license and service revenue.
Research and development expense fell to $22.3 million in Q2 2026 from $43.5 million as elritercept costs transitioned to Takeda and cibotercept spending declined; general and administrative expense decreased to $8.6 million. The company reported a Q2 net loss of $28.7 million and a first-half net loss of $52.4 million, compared with $117.8 million of net income in the prior-year period.
Cash and cash equivalents were $257.6 million as of June 30 2026, with total liabilities of $25.3 million, and management believes this will fund operations for at least 12 months. Elritercept is licensed globally (ex‑China) to Takeda, with potential milestones exceeding $1.1 billion; a $20 million development milestone was achieved in July 2026, of which 25% of net cash proceeds is expected to be distributed to stockholders. Lead asset rinvatercept is in a Phase 2 DMD trial with initial data expected in the first half of 2027, and regulatory engagement for an ALS Phase 2 study planned for the second half of 2026.
Keros Therapeutics, Inc. reported that it has issued a press release with its financial results for the quarter ended June 30, 2026. The press release, dated August 3, 2026, is provided as Exhibit 99.1 and is incorporated by reference for those detailed figures and disclosures.
Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under their license agreement for elritercept, triggered by dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial.
Under the global license, effective January 16, 2025, Keros previously received a $200 million upfront cash payment, is eligible for additional development, commercial and sales milestones that could exceed $1.1 billion, and may earn tiered royalties on net sales. Keros expects to distribute 25% of the net cash proceeds from this milestone payment to stockholders after receipt.
BlackRock, Inc. reports beneficial ownership of common stock of Keros Therapeutics, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 1,671,343 shares of Keros common stock, representing 8.4% of the class.
BlackRock has sole voting power over 1,645,352 shares and sole dispositive power over 1,671,343 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Keros’s outstanding common shares.
Keros Therapeutics, Inc. disclosed that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities. The Board appointed Corporate Controller and Vice President, Finance, Annita Tanini, age 55, as interim principal financial officer and principal accounting officer effective August 4, 2026, while a search for a new CFO is underway.
Under a new executive employment agreement, Ms. Tanini will receive an annual base salary of $302,300 and be eligible for an annual cash bonus targeted at 30% of base salary. If terminated without cause or she resigns for good reason, she may receive six months of base salary and up to six months of COBRA premium payments, subject to a release. Mr. Regnante will receive accrued salary and standard benefits under his existing employment agreement and is not entitled to additional severance beyond amounts required by law.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, increasing his direct holdings to 18,592 shares.